Ardelyx: Peak sales of up to $2.0 billion in 2035 could be possible - Jefferies raises the price target from $7 to $15!

Innovative Mechanisms in Kidney and Gastrointestinal Therapy Ardelyx (ARDX) has positioned itself as a biopharmaceutical company that explores fundamentally new mechanisms of action to address previously unmet medical needs. At the core of the technological platform and the most important solution offered to customers is the active ingredient Tenapanor. This inhibitor of sodium-hydrogen exchanger 3 (NHE3) forms the basis for the two main commercial products of the company: IBSRELA and XPHOZAH. For patients and physicians, Ardelyx provides critical...